newsfilter
← Latest News
GlobeNewswire·

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30,